PRIVATE INSURERS ARE PUTTING A PRICE TAG ON YOUR HEALTH.

Many private insurers have implemented review mechanisms for new innovative medicines to try to contain costs. If these reviews are focused only on cost utility, it can mean many new medications do not get approved, and Canadians cannot access them. Two-thirds of CARP members believe these review processes should be either completely transparent, giving plan members and sponsors a say in these decisions, or eliminated altogether.